BACKGROUND/AIMS: Acute @entity788 is a serious complication of diagnostic and therapeutic Endoscopic Retrograde Cholangiopancreatography (ERCP). In addition, serum pancreatic enzymes increase without symptoms in about 40-50% of @entity1 undergoing these endoscopic procedures. In order to evaluate the efficacy of @entity2390 in the prevention of these complications, we performed this randomised, prospective study. METHODOLOGY: We studied 73 @entity1 (31 males, 42 females), mean age 63.3 +/- 12.9 years (range 28-87 yrs). The @entity1 were randomly allocated into two groups (A and B). Group A (37 @entity1 ) was given 0.1 mg of @entity2390 subcutaneously 30 min before and 8 and 16 hours after the procedure, and group B (36 @entity1 ) was given a placebo. Serum amylase was measured 30 min before and 3 and 6 hrs after ERCP. All @entity1 were subjected to ultrasonography for signs of @entity788 . There was no statistically significant difference between the two groups concerning age, sex and indication for ERCP. Endoscopic sphincterotomy (ES) was performed in 14 @entity1 of group A and 10 @entity1 of group B. RESULTS: There were 4 cases of acute @entity788 in each group and the mean serum amylase at 3 and 6 hrs was comparable (494/676 and 429/582 IU/L, respectively). In comparing @entity1 who were subjected to either diagnostic or therapeutic ERCP, there was no statistically significant difference concerning episodes of acute @entity788 and the level of serum amylase. CONCLUSION: @entity2390 does not seem to prevent acute @entity788 and hyperamylasaemia after diagnostic and therapeutic ERCP.

The effect of @entity2390 on the prevention of acute XXXX and hyperamylasemia after diagnostic and therapeutic ERCP.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis', 'pancreatic inflammation'] @entity2390 :: ('MESH:D015282', 'Chemical') :: ['octreotide', 'Octreotide']
@entity788 :: (MESH:D010190,Disease) :: ['pancreatitis']
